10-Q: Procyon Corporation Reports Slight Revenue Increase but Operating Loss Widens in Q2 2024

Procyon Corporation's Q2 2024 shows a marginal revenue increase but a significant rise in operating expenses, leading to a larger operating loss compared to the previous year.

Summary

• Procyon Corporation's net sales for the quarter ended December 31, 2023, increased by approximately 1% to $1,200,053 compared to $1,183,937 in the same quarter of the previous year.
• For the six months ended December 31, 2023, net sales also increased by approximately 1% to $2,373,160 compared to $2,359,640 in the prior year period.
• Gross profit for the quarter increased by 5% to $936,729, with gross profit margin improving to 78% from 75%.
• Gross profit for the six months increased by 9% to $1,849,131, with gross profit margin improving to 78% from 75%.
• Operating expenses for the quarter increased by 13% to $1,038,144, driven by higher salaries, benefits, and administrative expenses.
• Operating expenses for the six months increased by 21% to $2,007,937, driven by higher salaries, benefits, and administrative expenses.
• The operating loss for the quarter widened to $101,415 from $31,545 in the prior year's quarter.
• The operating loss for the six months widened to $158,806 from $42,998 in the prior year's period.
• The company had cash of $267,804, inventories of $530,863, and net accounts receivable of $509,608 as of December 31, 2023.
• The company has $570,944 in Certificate of Deposits.
• The company had net working capital of $1,524,127 and long-term lease liabilities of $230,576 as of December 31, 2023.
• The company had consolidated income tax net operating loss carryforwards for federal income tax purposes of approximately $863,000 as of December 31, 2023.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the increased operating loss and identified material weakness in internal controls, despite a marginal increase in net sales and improved gross profit margins.

Positives

• Net sales experienced a slight increase for both the three and six months ended December 31, 2023.
• Gross profit margins improved to 78% for both the three and six months ended December 31, 2023, compared to 75% in the corresponding periods of the previous year, attributed to a shift in sales channels.
• The company has liquid assets including cash of $267,804, inventories of $530,863, and net accounts receivable of $509,608 as of December 31, 2023.
• The company has $570,944 in Certificate of Deposits.

Negatives

• Operating expenses increased significantly, rising by 13% for the quarter and 21% for the six months ended December 31, 2023.
• The operating loss widened to $101,415 for the quarter and $158,806 for the six months ended December 31, 2023.
• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in internal controls over financial reporting related to inadequate segregation of duties.
• The company had a valuation allowance of $176,532 as of December 31, 2023.

Risks

• The company's disclosure controls and procedures were deemed ineffective due to a material weakness in internal controls over financial reporting related to inadequate segregation of duties.
• The recoverability of deferred tax assets is directly dependent upon future operating results and may differ materially from estimates.
• Increased operating expenses are contributing to a widening operating loss.
• The company acknowledges risks related to business conditions in the skin and wound care market, competitive factors, changes in product mix, production delays, product recalls, loss of significant customers or suppliers, general supply chain delays, rising inflation, cyber security breaches, natural disaster impacts, and the impact of the COVID-19 pandemic.

Future Outlook

The report contains forward-looking statements regarding possible or assumed future results of operations, markets for products, anticipated expenditures, regulatory developments, competition, and other risks or uncertainties detailed in the Company's Securities and Exchange Commission filings.

Management Comments

• In fiscal 2023 to date, management has expanded on the services and options the Company provides for its customers.
• We have introduced a new Rolled Gauze form of our Amerx Branded Collagen Wound Care Kits.
• We also introduced a gel form of our Collagen products.
• During fiscal 2024, the Company will continue to address changes needed to improve segregation of duties consistent with control objectives.
• We have added staff to grow sales.
• We expect that increased sales will enable us to add support staff, specifically in the accounting and shipping departments.
• A secondary effect of adding more staff will address needed improvements in segregation of duties consistent with control objectives.

Industry Context

The report mentions business conditions in the skin and wound care market as a factor influencing the company's performance, suggesting that industry trends and competitive pressures are relevant to Procyon Corporation's results.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• Without detailed competitor analysis or market share data, it's difficult to assess Procyon's performance relative to industry peers.
• Companies like Integra LifeSciences, Smith & Nephew, and Mölnlycke Health Care are major players in the advanced wound care market, and a comparison of Procyon's growth rate, profitability, and product innovation to these companies would provide valuable context.
• Similarly, comparing Procyon's operating margins and sales efficiency to those of smaller, similarly sized companies in the medical device or wound care space would offer a more granular assessment of its financial health.

Related Party Transactions

• The line of credit is guaranteed by Justice W. Anderson, President and Chief Executive Officer.

Stakeholder Impact

• Shareholders may be concerned about the widening operating loss and the material weakness in internal controls.
• Employees may be affected by shifts in personnel needs and competitive pressures on salaries.
• Customers may be impacted by the introduction of new product forms (Rolled Gauze and gel form of Collagen products).

Next Steps

• The Company will continue to address changes needed to improve segregation of duties consistent with control objectives during fiscal 2024.
• The company expects that increased sales will enable them to add support staff, specifically in the accounting and shipping departments.

Key Dates

Keywords

financial statements, operating loss, net sales, internal controls, gross profit, Procyon Corporation, Form 10-Q